Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis

David,Marion; Ribeiro,Johnny; Descotes,Françoise; Serre,Claire-Marie; Barbier,Maryse; Murone,Maximilien; Clézardin,Philippe; Peyruchaud,Olivier

doi:10.3892/ijo.2011.1309

Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis

Authors:
- Marion David
- Johnny Ribeiro
- Françoise Descotes
- Claire-Marie Serre
- Maryse Barbier
- Maximilien Murone
- Philippe Clézardin
- Olivier Peyruchaud
View Affiliations

Affiliations: INSERM, UMR1033, Faculté de Médecine Lyon Est, Lyon, France, INSERM UMR1033, Faculté de Médecine Lyon-Est, Domaine Laennec, Rue Guillaume Paradin, 69372 Lyon cedex 08, France
Published online on: December 20, 2011 https://doi.org/10.3892/ijo.2011.1309
Pages: 1133-1141

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis is the main cause of death for cancer patients. Targeting factors that control metastasis formation is a major challenge for clinicians. Lysophosphatidic acid (LPA) is a bioactive phospholipid involved in cancer. LPA activates at least six independent G protein-coupled receptors (LPA1-6). Tumor cells frequently co-express multiple LPA receptors, puzzling the contribution of each one to cancer progression. All three receptors, LPA1, LPA2 and LPA3, act as oncogenes and prometastatic factors in the mouse mammary gland. The competitive inhibitor of LPA1 and LPA3 receptors, Ki16425, inhibits efficiently breast cancer bone metastases in animal models. We showed here that Debio 0719, which corresponds to the R-stereoisomer of Ki16425 exhibited highest antagonist activities at LPA1 (IC50=60 nM) and LPA3 (IC50=660 nM) than Ki16425 [IC50=130 nM (LPA1); IC50=2.3 µM (LPA3)]. In vitro, Debio 0719, inhibited LPA-dependent invasion of the 4T1 mouse mammary cancer cells. In vivo, early but not late administration of Debio 0719 (50 mg/kg p.o. twice daily) to BALB/c mice during the course of orthotopic 4T1 primary tumor growth reduced the number of spontaneously disseminated tumor cells to bone and lungs without affecting the growth of primary tumors and tumor-induced angiogenesis. We found that increased LPA1 mRNA expression in primary tumors of breast cancer patients correlated significantly with their positive lymph node status (p<0.001). Altogether, our results suggest that LPA1 controls early events of metastasis independently of cell proliferation and angiogenesis. Therefore, targeting this receptor with Debio 0719 has a high therapeutic potential against metastasis formation for breast cancer patients.

View Figures

View References

1	Choi JW, Herr DR, Noguchi K, et al: LPA receptors, subtypes and biological actions. Annu Rev Pharmacol Toxicol. 50:157–186. 2010. View Article : Google Scholar : PubMed/NCBI
2	Chun J, Hla T, Lynch KR, Spiegel S and Moolenaar WH: Inter-national Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature. Pharmacol Rev. 62:579–587. 2010. View Article : Google Scholar : PubMed/NCBI
3	An S, Bleu T, Hallmark OG and Goetzl EJ: Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem. 273:7906–7910. 1998. View Article : Google Scholar : PubMed/NCBI
4	Lin ME, Herr DR and Chun J: Lysophosphatidic acid LPA. receptors, signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 91:130–138. 2010. View Article : Google Scholar : PubMed/NCBI
5	Eichholtz T, Jalink K, Fahrenfort I and Moolenaar WH: The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J. 291:677–680. 1993.PubMed/NCBI
6	Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E and Liotta LA: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 267:2524–2529. 1992.PubMed/NCBI
7	Umezu-Goto M, Kishi Y, Taira A, et al: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 158:227–233. 2002. View Article : Google Scholar : PubMed/NCBI
8	Mills GB and Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 3:582–591. 2003. View Article : Google Scholar : PubMed/NCBI
9	Schulte KM, Beyer A, Kohrer K, Oberhauser S and Roher HD: Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells, over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer. 92:249–256. 2001. View Article : Google Scholar : PubMed/NCBI
10	Fang X, Schummer M, Mao M, et al: Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 1582:257–264. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kitayama J, Shida D, Sako A, et al: Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 6:R640–R646. 2004. View Article : Google Scholar : PubMed/NCBI
12	Shida D, Watanabe T, Aoki J, et al: Aberrant expression of lysophosphatidic acid LPA., receptors in human colorectal cancer. Lab Invest. 84:1352–1362. 2004. View Article : Google Scholar : PubMed/NCBI
13	Liu S, Umezu-Goto M, Murph M, et al: Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 15:539–550. 2009. View Article : Google Scholar : PubMed/NCBI
14	Boucharaba A, Serre C-M, Gres S, et al: Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 114:1714–1725. 2004. View Article : Google Scholar : PubMed/NCBI
15	David M, Wannecq E, Descotes F, et al: Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One. 5:e97412010. View Article : Google Scholar : PubMed/NCBI
16	Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P and Peyruchaud O: The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA. 103:9643–9648. 2006. View Article : Google Scholar : PubMed/NCBI
17	Ohta H, Sato K, Murata N, et al: Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 64:994–1005. 2003. View Article : Google Scholar : PubMed/NCBI
18	Lelekakis M, Moseley JM, Martin TJ, et al: A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 17:163–170. 1999. View Article : Google Scholar : PubMed/NCBI
19	Hama K, Aoki J, Fukaya M, et al: Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem. 279:17634–17639. 2004. View Article : Google Scholar : PubMed/NCBI
20	Pradere JP, Klein J, Gres S, et al: LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol. 18:3110–3118. 2007. View Article : Google Scholar : PubMed/NCBI
21	Aslakson CJ and Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52:1399–1405. 1992.PubMed/NCBI
22	Akhtari M, Mansuri J, Newman KA, Guise TM and Seth P: Biology of breast cancer bone metastasis. Cancer Biol Ther. 7:3–9. 2007. View Article : Google Scholar
23	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
24	Jeon ES, Lee IH, Heo SC, et al: Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism. Biochim Biophys Acta. 1801:1205–1213. 2010. View Article : Google Scholar
25	Donegan WL: Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 47:28–51. 1997. View Article : Google Scholar : PubMed/NCBI
26	Eyles J, Puaux AL, Wang X, et al: Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest. 120:2030–2039. 2010. View Article : Google Scholar : PubMed/NCBI
27	Witt AE, Hines LM, Collins NL, et al: Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res. 5:599–610. 2006. View Article : Google Scholar : PubMed/NCBI
28	Taghavi P, Verhoeven E, Jacobs JJ, et al: In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene. 27:6806–6816. 2008. View Article : Google Scholar : PubMed/NCBI
29	Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer, A R andomized, double-blind study. J Clin Oncol. 28:5132–5139. 2010. View Article : Google Scholar
30	Noguchi K, Herr D, Mutoh T and Chun J: Lysophosphatidic acid LPA. and its receptors. Curr Opin Pharmacol. 9:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
31	Boucharaba A, Guillet B, Menaa F, Hneino M, van Wijnen AJ, Clezardin P and Peyruchaud O: Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol Res. 18:173–184. 2009. View Article : Google Scholar
32	Li TT, Alemayehu M, Aziziyeh AI, et al: Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res. 7:1064–1077. 2009. View Article : Google Scholar : PubMed/NCBI
33	Steeg PS, Bevilacqua G, Pozzatti R, Liotta LA and Sobel ME: Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res. 48:6550–6554. 1998.PubMed/NCBI
34	Steeg PS, Horak CE and Miller KD: Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res. 14:5006–5012. 2008. View Article : Google Scholar : PubMed/NCBI
35	Horak CE, Lee JH, Elkahloun AG, et al: Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res. 67:7238–7246. 2007. View Article : Google Scholar : PubMed/NCBI
36	Horak CE, Mendoza A, Vega-Valle E, et al: Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res. 67:11751–11759. 2007. View Article : Google Scholar : PubMed/NCBI
37	Berthier A, Seguin S, Sasco AJ, et al: High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer. Br J Cancer. 102:1024–1031. 2010. View Article : Google Scholar : PubMed/NCBI
38	Boissier S, Ferreras M, Peyruchaud O, et al: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60:2949–2954. 2000.PubMed/NCBI